Company Profile: Schering AG: analysis of patenting 1992 - 1995

Abstract

Schering AG, a company which pioneered oral contraceptives, still specialises in fertility control agents and related therapies. In this review of the Company's recent patenting, steroids, prostaglandins and thromboxanes all feature prominently, but research is shown to have broadened into such areas as cancer therapy, dermatology and antithrombotics. Remarkably, no anti-infectives are under investigation. There are also well-characterised leukotriene B₄ and excitatory amino acid antagonist projects, and the Company should now be in a position to identify compounds for preclinical investigation, thereby rectifying an imbalance in its current development pipeline.